NCT04497272

Assesment of the Metabolomic Signature in COVID-19 Patients

Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.

Conditions

• COVID 19

Interventions

Type	Name	Description
OTHER	COVID-19 patients	It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.

Timeline

• Start date: 2020-08-07
• Primary completion: 2021-03-01
• Completion: 2022-07-31
• First posted: 2020-08-04
• Last updated: 2022-08-31

Locations

1 site across 1 country: France